BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 18, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/15 cls
Anesiva (ANSV) Susquehanna Angela Larson New Neutral -8% $6.76
Larson expects ANSV to launch its Zingo topical local anesthetic for pediatric anesthetic pre-venipuncture this year. She also said the company's most potentially valuable compound is ALGRX4975, a capsaicin injection in Phase II testing to treat post-operative pain and moderate to severe osteoarthritic pain. She expects ALGRX4975 to move into Phase III in 2008.
Celera (CRA) JMP Securities Charles Duncan New Underperform 5% $13.51
Duncan set an $11 target, which reflects his concerns that CRA has a maturing core business and faces "significant" hurdles in the molecular diagnostics market. He thinks the company will need dilutive M&A transactions in molecular diagnostics over the next 12-24 months and believes that positive expectations for the MDx sector are already priced into the stock.

Read the full 821 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >